{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:10:02Z","timestamp":1790622602538,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejphar.2023.175675","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T21:31:03Z","timestamp":1679520663000},"page":"175675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach"],"prefix":"10.1016","volume":"947","author":[{"given":"Grant","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mecham","family":"Groneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Blavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-9857","authenticated-orcid":false,"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175675_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ejphar.2023.175675_bib2","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejphar.2023.175675_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.175675_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2023.175675_bib7","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1542\/peds.2018-0333I","article-title":"Cardiac management of the patient with duchenne muscular dystrophy","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejphar.2023.175675_bib8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/1060028019900500","article-title":"A review of deflazacort for patients with duchenne muscular dystrophy","volume":"54","author":"Bylo","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.175675_bib9","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1542\/peds.2018-0333D","article-title":"Rehabilitation management of the patient with duchenne muscular dystrophy","volume":"142","author":"Case","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejphar.2023.175675_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175675_bib11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.410160612","article-title":"Muscle fiber degeneration and necrosis in muscular dystrophy and other muscle diseases: cytochemical and immunocytochemical data","volume":"16","author":"Cornelio","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejphar.2023.175675_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejphar.2023.175675_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2023.175675_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416080","article-title":"Histological methods to assess skeletal muscle degeneration and regeneration in duchenne muscular dystrophy","volume":"23","author":"Dubuisson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175675_bib18","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejphar.2023.175675_bib19","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.175675_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00431-018-3272-1","article-title":"Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study","volume":"178","author":"Hilhorst","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ejphar.2023.175675_bib21","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.175675_bib22","series-title":"FDA issues complete response letter for kyndrisa for duchenne muscular dystrophy amenable to exon 51 skipping","author":"Inc","year":"2016"},{"key":"10.1016\/j.ejphar.2023.175675_bib23","series-title":"A treatment option for amenable patients | EXONDYS 51 (eteplirsen) injection","author":"Inc","year":"2020"},{"key":"10.1016\/j.ejphar.2023.175675_bib24","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","article-title":"Precision medicine through antisense oligonucleotide-mediated exon skipping","volume":"39","author":"Li","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2023.175675_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejphar.2023.175675_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.175675_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2023.175675_bib30","series-title":"Support for Healthcare Professionals - VILTEPSO","author":"NS-Pharma","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175675_bib31","series-title":"VILTEPSO [package Insert]","author":"NS-Pharma","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175675_bib32","first-page":"121","article-title":"Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.ejphar.2023.175675_bib33","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1097\/BRS.0b013e3181fea1ed","article-title":"The natural history of cardiac and pulmonary function decline in patients with duchenne muscular dystrophy","volume":"36","author":"Roberto","year":"2011","journal-title":"Spine (Phila Pa 1976"},{"key":"10.1016\/j.ejphar.2023.175675_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of duchenne and becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejphar.2023.175675_bib35","series-title":"EXONDYS 51 [package Insert]","author":"Sarepta-Therapeutics","year":"2020"},{"key":"10.1016\/j.ejphar.2023.175675_bib36","series-title":"AMONDYS 45 [package Insert]","author":"Sarepta-Therapeutics","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175675_bib37","series-title":"VYONDYS 53 [package Insert]","author":"Sarepta-Therapeutics","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175675_bib38","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","article-title":"Respiratory management of the patient with duchenne muscular dystrophy","volume":"142","author":"Sheehan","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejphar.2023.175675_bib39","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/CON.0000000000000791","article-title":"The dystrophinopathies","volume":"25","author":"Thangarajh","year":"2019","journal-title":"Continuum"},{"key":"10.1016\/j.ejphar.2023.175675_bib40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00256-011-1240-1","article-title":"Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study","volume":"41","author":"Torriani","year":"2012","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ejphar.2023.175675_bib41","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","article-title":"Bone health and osteoporosis management of the patient with duchenne muscular dystrophy","volume":"142","author":"Ward","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejphar.2023.175675_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/genes13020257","article-title":"Antisense and gene therapy options for duchenne muscular dystrophy arising from mutations in the N-terminal hotspot","volume":"13","author":"Wilton-Clark","year":"2022","journal-title":"Genes"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:20:34Z","timestamp":1757978434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"alternative-id":["S0014299923001863"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175675","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175675"}}